274 related articles for article (PubMed ID: 14711309)
1. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
3. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
[TBL] [Abstract][Full Text] [Related]
4. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Sanders JM; Song Y; Chan JM; Zhang Y; Jennings S; Kosztowski T; Odeh S; Flessner R; Schwerdtfeger C; Kotsikorou E; Meints GA; Gómez AO; González-Pacanowska D; Raker AM; Wang H; van Beek ER; Papapoulos SE; Morita CT; Oldfield E
J Med Chem; 2005 Apr; 48(8):2957-63. PubMed ID: 15828834
[TBL] [Abstract][Full Text] [Related]
5. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Kotsikorou E; Oldfield E
J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
[TBL] [Abstract][Full Text] [Related]
6. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates.
Cheng F; Oldfield E
J Med Chem; 2004 Oct; 47(21):5149-58. PubMed ID: 15456258
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
10. Activity of sulfonium bisphosphonates on tumor cell lines.
Zhang Y; Hudock MP; Krysiak K; Cao R; Bergan K; Yin F; Leon A; Oldfield E
J Med Chem; 2007 Nov; 50(24):6067-79. PubMed ID: 17963374
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
Hudock MP; Sanz-Rodríguez CE; Song Y; Chan JM; Zhang Y; Odeh S; Kosztowski T; Leon-Rossell A; Concepción JL; Yardley V; Croft SL; Urbina JA; Oldfield E
J Med Chem; 2006 Jan; 49(1):215-23. PubMed ID: 16392806
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
13. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
14. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
15. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Ghosh S; Chan JM; Lea CR; Meints GA; Lewis JC; Tovian ZS; Flessner RM; Loftus TC; Bruchhaus I; Kendrick H; Croft SL; Kemp RG; Kobayashi S; Nozaki T; Oldfield E
J Med Chem; 2004 Jan; 47(1):175-87. PubMed ID: 14695831
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.
Li J; Herold MJ; Kimmel B; Müller I; Rincon-Orozco B; Kunzmann V; Herrmann T
J Immunol; 2009 Jun; 182(12):8118-24. PubMed ID: 19494338
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
18. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate inhibition of phosphoglycerate kinase: quantitative structure-activity relationship and pharmacophore modeling investigation.
Kotsikorou E; Sahota G; Oldfield E
J Med Chem; 2006 Nov; 49(23):6692-703. PubMed ID: 17154500
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
